Clinical Trials Browser

Unknown × Recurrence × Bendamustine Hydrochloride × Clear all

NCT05757466 2023-12-19

Prolgo-HL

Phase 2 Unknown

Hodgkin Disease, Recurrence

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01884441 2014-01-29

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Phase 2 Unknown

Hodgkin Disease, Lymphoma, Recurrence

NCT01686386 2013-04-05

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT00385125 2006-10-06

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase 2 Unknown

Lymphoma, Non-Hodgkin, Recurrence